CStone Pharmaceuticals (HKG:2616) has submitted a clinical trial application in Australia for CS2009, a drug for solid tumors, according to a Monday filing with the Hong Kong bourse.
CS2009 is a tri-specific antibody that targets PD-1, VEGFA, and CTLA-4 to treat major cancers. It has shown promise for treating various cancers, including lung, ovarian, kidney, cervical, liver, and stomach, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.